NCT01254630View on ClinicalTrials.gov

A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011)

PHASE3CompletedINTERVENTIONAL

Enrollment

5,305

Participants

Timeline

Start Date

June 24, 2011

Primary Completion Date

April 11, 2017

Study Completion Date

April 11, 2017

Conditions

Herpes Zoster

Interventions

BIOLOGICAL

V212

V212 viral antigen for HZ, 0.5 mL subcutaneous (SC) injection per dose, in a four dose regimen, approximately 30 days apart.

BIOLOGICAL

Placebo

Vaccine stabilizer for V212 with no virus antigen, 0.5 mL SC injection per dose, in a four dose regimen, approximately 30 days apart.

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01254630 - A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011) | Biotech Hunter | Biotech Hunter